Clinical Trial Update: EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer [NA]

View source ↗

Summary

A trial evaluating EF5 as a biomarker of tumor hypoxia in high-grade soft tissue sarcoma and squamous cell carcinoma of the lip/oral cavity has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma
• Squamous Cell Carcinoma of the Lip and Oral Cavity

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | NA | Status: TERMINATED